Roche’s Vabysmo Chases Regeneron’s Eylea With New Pivotal Macular Edema Wins
Executive Summary
The Swiss major’s new bispecific antibody could challenge Eylea’s standard of care status in another ophthalmic indication, macular edema due to retinal vein occlusion, but the older rival is set to hit back in bigger markets with a high-dose reformulation.
You may also be interested in...
Vabysmo Is Bright Spot For Roche In Bumpy Q3
Roche's pharma revenues declined in the third quarter, but the Swiss major is hoping that Tecentriq in adjuvant settings can boost future revenues – and that, just maybe, it will have a win from its Alzheimer’s candidate too.
Aridis' Monoclonal Antibody Rouses Analyst Optimism Despite Pneumonia Phase III Miss
The US biotech’s lead candidate missed the mark in a Phase III hospital-related pneumonia trial due to low recruitment affected by macroeconomic headwinds but analysts retain high hopes for another upcoming study.
Grey Wolf Raises $49m To Bring ‘Tumor Unmasking’ Candidate To Clinic
The UK biotech will use the funds to advance the development of its first-in-class ERAP1 inhibitor, which could circumvent the limitations of poor tumor visibility and T cell exhaustion.